by Jon Rappoport at Jon Rappoport’s Blog
The CDC has issued a document that bulges with devastating admissions.
The release is titled, “07/21/2021: Lab Alert: Changes to CDC RT-PCR for SARS-CoV-2 Testing.” It begins explosively:
“After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.”
Many people believe this means the CDC is giving up on the PCR test as a means of “detecting the virus.” The CDC isn’t saying that at all.
They’re saying the PCR technology will continue to be used, but they’re replacing what the test is looking FOR with a better “reference sample.” A better marker. A better target. A better piece of RNA supposedly derived from SARS-CoV-2.
CDC/FDA are confessing there has been a PROBLEM with the PCR test which has been used to detect the virus, starting in February of 2020—right up to this minute.
In other words, the millions and millions of “COVID cases” based on the PCR test in use are all suspect. Actually, that statement is too generous. Every test result of every PCR test should be thrown out.
To confirm this, the CDC document links to an FDA release titled, “SARS-CoV-2 Reference Panel Comparative Data.” Here is a killer quote:
“During the early months of the Coronavirus Disease 2019 (COVID-19) pandemic, clinical specimens [of the virus] were not readily available to developers of IVDs [in vitro diagnostics] to detect SARS-CoV-2. Therefore, the FDA authorized IVDs based on available data from contrived samples generated from a range of SARS-CoV-2 material sources (for example, gene specific RNA, synthetic RNA, or whole genome viral RNA) for analytical and clinical performance evaluation. While validation using these contrived specimens provided a measure of confidence in test performance at the beginning of the pandemic, it is not feasible to precisely compare the performance of various tests that used contrived specimens because each test validated performance using samples derived from different gene specific, synthetic, or genomic nucleic acid sources.”
Translation: We, at the CDC…
Continue Reading